Multi-parametric Imaging in Personalized Radiotherapy
A Technical Framework for Combining Multi-parametric Imaging With Advanced Modelling in Personalized Radiotherapy
CNAO National Center of Oncological Hadrontherapy
35 participants
Apr 19, 2022
OBSERVATIONAL
Conditions
Summary
The study consists in the retrospective and prospective collection of imaging data (along with clinical information related to treatment) of skull-base chordoma patients treated with particle therapy, to derive imaging biomarkers which, integrated with advanced mathematical models, will allow predicting treatment outcome on a multi-scale basis.
Eligibility
Inclusion Criteria6
- Patients with histologically confirmed diagnosis of chordoma of the skull base
- Particle therapy with curative intent
- Karnofsky Performance status greater than or equal to 60
- Patients with macroscopic disease detectable at pre-radiotherapy imaging
- Patients undergoing PT with standardized treatment procedures
- Patients who have signed the written informed consent for research
Exclusion Criteria7
- Metastatic disease
- Palliative treatment
- Other malignancies with disease-free interval < 5 years (excepting pre- cancerous lesions)
- Pregnancy
- Simultaneous CHT or Immunotherapy
- Extensive metal instrumentation/implants
- Patients with autoimmune diseases (ADs) -including collagen-vascular (CVD) and inflammatory bowel (IBD)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05888064